LRMR News and Press, Larimar Therapeutics Inc. From 05/20/24

2024-05-20 18:17:01 ET More on Larimar Therapeutics Seeking Alpha’s Quant Rating on Larimar Therapeutics Historical earnings data for Larimar Therapeutics Financial information for Larimar Therapeutics Read the full article on Seeking Alpha For...

Food and Drug Administration (FDA) removed partial clinical hold following review of Phase 2 dose exploration study data Ongoing open label extension (OLE) study initially evaluating 25 mg; Larimar plans to dose escalate to 50 mg following further characterization of frataxin pharmacodyna...

2024-05-09 17:05:29 ET More on Larimar Therapeutics Larimar Therapeutics rises after pricing $150M stock offering Larimar Therapeutics announces proposed underwritten public offering Seeking Alpha’s Quant Rating on Larimar Therapeutics Historical earni...

2024-05-09 07:56:23 ET More on Larimar Therapeutics Larimar Therapeutics rises after pricing $150M stock offering Larimar Therapeutics announces proposed underwritten public offering Seeking Alpha’s Quant Rating on Larimar Therapeutics Historical earni...

First patient dosed in open label extension (OLE) study with 25 mg daily dosing of nomlabofusp; interim data on track for Q4 2024 Positive top-line Phase 2 dose exploration study data demonstrated nomlabofusp was generally well-tolerated with dose-dependent increases in tissue frataxin le...

2024-04-26 19:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-16 22:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-03 11:00:03 ET Joori Park from Leerink Partners issued a price target of $25.00 for LRMR on 2024-04-03 09:14:00. The adjusted price target was set to $25.00. At the time of the announcement, LRMR was trading at $7.57. The overall price target consensus is at $4.0...

2024-03-18 02:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-14 17:09:11 ET More on Larimar Therapeutics Larimar Therapeutics rises after pricing $150M stock offering Larimar Therapeutics announces proposed underwritten public offering Read the full article on Seeking Alpha For further details see: Larimar ...